Dave Inc. (NASDAQ:DAVE) is one of the cheap rising stocks to buy now. On March 13, William Blair reiterated an Outperform rating on Dave Inc (NASDAQ:DAVE) following a meeting with the company’s CFO, Kyle Beilman. Dave Inc. (DAVE) Explodes on AI Integration and New Product Plans amid Organic Growth Pixabay/Public Domain The research firm remains confident in the company’s outlook, as it has differentiated itself through a data-driven, algorithmic, credit-first approach. Its solutions address a total addr ...

In an era where AI-driven innovation is reshaping entire industries, valuation models may overlook true growth opportunities. This could lead to a narrow focus on the technology driving a company's revenue, which could lead investors astray when it comes to the fundamentals. This is where RONB differentiates itself. It uses a "first principles†approach — championed by Ron Baron, David Baron, and Michael Baron — to deconstruct the complexity of a business by breaking it down to its essential elements: its cu ...

Financial Data and Key Metrics Changes - In 2025, total revenue reached $959.5 million, a 61.4% year-over-year increase, with gross profit more than doubling [34] - Adjusted net profit was approximately $230.3 million, reflecting a 285% year-over-year growth from $59.8 million in FY 2024 [38] - The company recorded a loss of $532.4 million due to share loss and impairment from the investment in Legend Biotech [35][36] Business Line Data and Key Metrics Changes - GenScript Life Science Group revenue grew 14.8% year-over-year to $522.1 million, contributing significantly to overall growth [34] - ProBio achieved a remarkable 309.1% year-over-year growth to $388.7 million, largely due to the LaNova license deal [34] - Bestzyme's revenue grew by 7.9% year-over-year to $58 million, outperforming the industry average of 5% [34] Market Data and Key Metrics Changes - North American and European markets contributed 38% of total revenue, indicating a notable increase in international footprint [41] - Orders from first-time clients in the Life Science Group grew over 34% year-over-year, reflecting strong market demand [9] - The U.S. market maintained steady growth, while Europe achieved over 30% growth in 2025 [10] Company Strategy and Development Direction - The company aims to achieve high-quality growth while gradually improving profitability, focusing on platform innovation and ecosystem expansion [46] - Strategic investments will be made in automation and digitalization to enhance operational efficiency and cost-effectiveness [46] - The company plans to strengthen its capabilities in business synergy, globalization, and automation as key focuses for 2026 [47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth trajectory of the GenScript Life Science Group, expecting revenue growth between 15% and 18% in 2026 [46] - The company noted that geopolitical uncertainties had a relatively minor impact on biopharmaceutical production capacity in 2025 [62] - Management highlighted the importance of maintaining market leadership and focusing on cost optimization to improve profitability [56] Other Important Information - GenScript achieved significant ESG milestones, including an upgrade to AA rating by MSCI and inclusion in the FTSE4Good index series [7] - The company reported a significant increase in R&D efficiency, achieving a 140% improvement and reducing project timelines to six months [32] Q&A Session Summary Question: Revenue recognition from LaNova deal - The company confirmed that the second milestone payment from the LaNova deal was recognized in the second half of 2025, contributing to strong organic growth [51] Question: Profitability and gross profit margin decline - Management explained that slight fluctuations in gross profit margins were due to necessary investments for global expansion and product mix shifts, with expectations for improvement in 2026 [55][56] Question: Outlook for global market share amid geopolitical uncertainties - Management expressed optimism about the long-term prospects for CRO and CDMO, citing a rebound in global biopharmaceutical investment and improved capacity utilization in China [62] Question: Development strategy for Legend Biotech - Management highlighted Legend's significant progress and profitability, stating that it will continue to evaluate options to maximize shareholder value [73] Question: Strategy to mitigate customer concerns regarding regulatory scrutiny - The company clarified that it is not classified as a genomics or gene therapy-related company and will enhance transparency and compliance to address customer concerns [75]

Financial Data and Key Metrics Changes - In 2025, the total revenue reached $959.5 million, a 61.4% year-over-year increase, with gross profit more than doubling [33] - Adjusted net profit was approximately $230 million, reflecting a 285% year-over-year growth from $59.8 million in FY 2024 [37] - Adjusted gross profit grew 12.5% year-over-year to $267.3 million, with an adjusted gross profit margin of 51.2% [39] Business Segment Data and Key Metrics Changes - The GenScript Life Science Group revenue grew 14.8% year-over-year to $522.1 million, with integrated gene-to-protein services accounting for nearly 65% of total revenue growth [33][38] - ProBio generated $388.7 million in total revenue, with a 21% organic growth excluding the LaNova deal [40] - Bestzyme's revenue grew by 7.9% year-over-year to $58 million, outperforming the industry average of 5% [33] Market Data and Key Metrics Changes - North American and European markets contributed 38% of total revenue, reflecting an enhanced international footprint [40] - Orders from first-time clients in the Life Science Group grew over 34% year-over-year, indicating strong market demand [9] - The Asia Pacific region, particularly Greater China, showed increased activities, contributing to overall growth [10] Company Strategy and Development Direction - The company aims to achieve high-quality growth while gradually improving profitability, focusing on platform innovation, ecosystem expansion, and automation [45] - Strategic investments will be made in differentiating technologies and operational efficiency improvements to enhance margins [54] - The company plans to expedite the establishment of commercial manufacturing capacity for sweet proteins, laying the foundation for international market expansion [46] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the long-term growth trajectory of the Life Science Group, anticipating revenue growth between 15% and 18% in 2026 [45] - The company noted that geopolitical uncertainties had a relatively minor impact on biopharmaceutical production capacity in 2025 [59] - Legend Biotech is expected to positively impact the company's financials in the long run, with its CAR-T franchise achieving profitability [70] Other Important Information - The company achieved significant progress in sustainability, receiving an upgraded ESG rating to AA from MSCI and being included in the FTSE4Good index series [7] - R&D investment increased significantly, with a focus on AI-powered molecular discovery and product optimization, achieving a 140% improvement in R&D efficiency [31] Q&A Session Summary Question: Revenue recognition from LaNova deal - The company confirmed that the second milestone payment from the LaNova deal was recognized in the second half of 2025, contributing to strong growth in the Life Sciences Group [50] Question: Profitability and gross profit margin decline - Management explained that gross profit fluctuations were due to necessary investments for global expansion and product mix shifts, with expectations for improved margins in 2026 through cost optimization and operational efficiency [53][54] Question: Outlook for Life Sciences business amid geopolitical uncertainties - Management expressed a highly optimistic outlook for the CRO and CDMO sectors, noting a rebound in global biopharmaceutical investment and a thriving trend in biotech R&D [59] Question: Development strategy for Legend Biotech - Management highlighted that Legend Biotech is a valuable asset, with significant progress expected to benefit the company's financials in the long run [70] Question: Strategy to mitigate customer concerns regarding regulatory scrutiny - The company clarified that it provides raw materials to gene therapy companies and is enhancing transparency and compliance to address regulatory concerns [72]

Reimagining the Path to Homeownership with AI-driven innovation The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction, including India, in which such offer, solicitation or sale would require preparation of a prospectus or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any ...

Core Insights - Artisan Mid Cap Fund's fourth-quarter 2025 performance showed a decline in its Investor Class (-0.44%), Advisor Class (-0.37%), and Institutional Class (-0.35%) compared to a -3.70% drop in the Russell Midcap® Growth Index, indicating relative resilience in a challenging market [1] Group 1: Fund Performance - The Fund seeks to invest in companies with franchise characteristics, strong earnings trajectories, and trading at a discount to estimated private market value [1] - Continued strength in information technology and health care sectors contributed positively to the Fund's performance during the quarter [1] Group 2: Roblox Corporation (NYSE:RBLX) - Roblox Corporation is highlighted as a significant detractor in Q4, with shares declining 42% despite a 21% increase for the year, amid concerns about sustaining growth momentum [3] - The company reported exceptional growth in 2025, with revenue and bookings increasing by 48% and 70% year-over-year, respectively, driven by popular games [3] - As of February 20, 2026, Roblox's stock closed at $62.00, with a market capitalization of $43.94 billion, and a one-month return of -16.23% [2] - Roblox is not among the 30 most popular stocks among hedge funds, with 83 hedge fund portfolios holding the stock at the end of Q4, down from 90 in the previous quarter [4]

Core Insights - Toast Inc. (TOST) is expected to report fourth-quarter 2025 earnings on February 12, with revenue estimated at $1.62 billion, reflecting a 21% increase year-over-year, and non-GAAP earnings per share projected at 24 cents, indicating a 380% year-over-year growth [1][2] Financial Performance - TOST has beaten the Zacks Consensus Estimate in two of the last four quarters, lagged in one, and matched in another, with an average surprise of -1.81%. The stock has decreased by 33.1% over the past year, compared to a 19.1% decline in the Zacks Internet-Software industry [2] - The fourth-quarter non-GAAP gross profit from subscription services and financial technology solutions is expected to be between $480 million and $490 million, representing a 22-25% year-over-year growth. Adjusted EBITDA is projected to be between $140 million and $150 million [4] Market Dynamics - Toast's fourth-quarter performance is anticipated to be influenced by record highs in Annual Recurring Revenue (ARR), strong revenue momentum, and increased adoption of AI-driven products. The company's ability to expand its total addressable market and leverage AI innovation is expected to enhance its long-term prospects [3][9] - A multi-year global partnership with Uber aims to enhance product innovation and market initiatives for restaurant growth, starting in the U.S. and Canada. This partnership will integrate Toast's POS platform with Uber's delivery network, improving digital ordering and guest experiences [5][8] Customer Growth - Toast added approximately 7,500 net new locations in the third quarter, bringing the total to 156,000 globally, a 23% year-over-year increase. This growth spans across small and medium-sized businesses (SMBs) as well as multi-location and enterprise customers, with ongoing international expansion [6][9] Strategic Initiatives - The company is positioning itself as a comprehensive operating system for restaurants, not just a point-of-sale provider. Recent product launches like Toast IQ and Toast Advertising are part of this strategy, aimed at optimizing operations and creating new revenue streams [9] - Management has indicated near-term challenges, including higher tariff costs and the need to manage payback periods while expanding into new markets. The company has also absorbed $31 million in bad debt and credit-related expenses [10]

Core Insights - The company is transitioning to a new strategy for 2026, building on the success of its 2025 strategy, which added $5 billion in sales and aims to drive top-tier growth and shareholder return [2][4] - The focus areas include strong global brands, investment in innovation, and leveraging omnichannel demand generation to enhance consumer engagement and brand penetration [1][2][5] Financial Performance - The company reported organic sales growth across all categories in Q4, with improved momentum compared to Q3, except in North America [3][4] - Despite challenges such as raw material inflation and tariffs, the company achieved growth in net sales, gross profit, and free cash flow in 2025 [4][6] Market Dynamics - Emerging markets outperformed developed markets, with significant growth in regions like Latin America and Asia, particularly in Mexico and Brazil, which saw high single-digit growth [7][41] - The geopolitical environment remains volatile, particularly in Latin America, impacting market conditions and category growth rates [8][7] Strategic Initiatives - The company is investing in digital capabilities, AI, and supply chain optimization to enhance efficiency and drive growth [5][6] - A strategic growth and productivity program has been announced to support the new strategy and improve organizational effectiveness [6][15] Consumer Trends - There is a noted shift in consumer behavior towards premium products, with the company focusing on innovation to capture this trend [37][64] - The company is adapting its marketing strategies to address economic uncertainties and changing consumer preferences, particularly in North America [32][69] Innovation and Product Development - The company is enhancing its innovation pipeline, particularly in premium segments, to drive growth and market share [12][64] - Successful product launches, such as the dual chamber technology for Hawley & Hazel, are being leveraged to improve market performance [27][22] Financial Guidance - The company has provided a wide range for its 2026 net sales and organic sales growth guidance, reflecting uncertainty in category growth [8][18] - Expectations for organic sales growth in 2026 are set between 1% to 4%, depending on market conditions [10][18]

Investment and Expansion Plans - Minister for Large and Medium Industries M B Patil engaged in high-level discussions with global company executives regarding investment and expansion plans during the World Economic Forum (WEF) Annual Meeting in Davos [1][9] - CFI Technologies announced readiness to inaugurate a data centre in Bengaluru and expressed interest in expanding into tier-2 cities [2][9] - Bharti Enterprises has invested approximately Rs 13,000 crore in Karnataka and discussed plans for an additional data centre in the state [2][9] Sector-Specific Investments - Philip Morris International is interested in investing in Karnataka for the manufacturing of next-generation smoke-free products, identifying the state as its second-largest global procurement location [3][9] - Carlsberg Group confirmed a Rs 350-crore investment for bottling capacity and indicated plans for further expansion in Karnataka [4][9] - Bharat Forge Limited sought information on further investment opportunities aligned with Karnataka's industrial and manufacturing ecosystem [9] Research and Development Initiatives - Imperial College London is considering establishing a research and development centre in KWIN City and aims to expand research activities in collaboration with local higher education institutions [5][9] - The university currently operates an innovation hub in Bengaluru and collaborates with the Indian Institute of Science (IISc) [5][9] Renewable Energy and Technology Discussions - Discussions were held with ReNew Power regarding renewable energy generation and storage opportunities [6][9] - Xylem Inc engaged in talks about smart wastewater treatment and tertiary treated water plants for industrial areas [6][9] - Octopus Energy discussed vehicle-to-grid technology and digital solutions for grid management [6][9] Digital Infrastructure and Talent Pool - PayPal emphasized Karnataka's significance to its global operations, highlighting Bengaluru's talent pool and discussing AI-driven innovation and startup ecosystem collaboration [7][9] - Sify Technologies announced a new data centre facility in Karnataka set for imminent inauguration and explored opportunities for data centre development in tier-2 cities [7][9] Government Commitment - The Karnataka government reaffirmed its commitment to policy continuity, regulatory certainty, and full facilitation to ensure the timely execution of investments discussed at WEF [8][9]

Core Insights - Unisys has been recognized as a leader in the 2025 Multi Public Cloud Services Provider Lens® report, marking the sixth consecutive year of such recognition by ISG [1][2] Group 1: Leadership Recognition - The report evaluates providers' capabilities in public cloud services, including migration, consulting, transformation, managed services, and financial operations services [1] - Unisys received seven leader designations across five quadrants in four regions, showcasing its strong market presence and innovative solutions [3][4] Group 2: Client-Centric Approach - The company emphasizes a client-first strategy, focusing on tools and solutions that facilitate cloud transformations for businesses [3] - Unisys integrates AI-driven innovation and automation into its offerings, particularly in regulated sectors, enhancing security and governance [4][7] Group 3: Service Offerings - Unisys provides tailored cybersecurity and compliance solutions for the U.S. Public Sector, ensuring the protection of sensitive data [7] - The company offers comprehensive cloud assessments and customizable FinOps solutions in Brazil, aimed at improving visibility and control over cloud expenditures [7]